TY - JOUR
T1 - Apolipoprotein E genotypes and the risk of Parkinson disease
AU - Gao, Jianjun
AU - Huang, Xuemei
AU - Park, Yikyung
AU - Liu, Rui
AU - Hollenbeck, Albert
AU - Schatzkin, Arthur
AU - Mailman, Richard B.
AU - Chen, Honglei
N1 - Funding Information:
This study was supported by the intramural research program of the National Institute of Environmental Health Sciences (Z01-ES-101986) and the National Cancer Institute (Z01 CP010196-02), R01 NS060722 (Dr. Huang), and a grant from the Pennsylvania Commonwealth Universal Research Enhancemehnt Program (Drs. Mailman and Huang).
PY - 2011/11
Y1 - 2011/11
N2 - We examined apolipoprotein E (ApoE) genotypes in relation to Parkinson's disease (PD) among 786 cases and 1537 controls, all non-Hispanic Caucasians. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from multivariate logistic regression models, adjusting for year of birth, sex, smoking status, daily caffeine intake, and family history of PD. Compared with participants with ApoE ε33, ε4 carriers (ε34/ε44) had significantly lower odds for having PD (OR, 0.75; 95% CI, 0.59-0.94; p = 0.01), whereas ε2 carriers (ε23/ε22) did not (OR, 0.95; 95% CI, 0.73-1.24; p = 0.71). Subgroup analyses showed similar results. In addition, we conducted a meta-analysis which confirmed our primary findings (ε34/ε44 vs ε33: OR, 0.90; 95% CI, 0.81-0.99; p = 0.024 and ε23/ε22 vs ε33: OR, 1.10; 95% CI, 0.97-1.23; p = 0.13). In PD patients, the prevalence of dementia appeared to be higher among ε4 carriers (compared with ε33: OR, 1.59; 95% CI, 0.98-2.58; p = 0.06), but lower among ε2 carriers (OR, 0.75; 95% CI, 0.40-1.42; p = 0.38), although neither test was statistically significant. Our study suggested that the ApoE ε4 allele may be associated with a lower PD risk among non-Hispanic Caucasians.
AB - We examined apolipoprotein E (ApoE) genotypes in relation to Parkinson's disease (PD) among 786 cases and 1537 controls, all non-Hispanic Caucasians. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from multivariate logistic regression models, adjusting for year of birth, sex, smoking status, daily caffeine intake, and family history of PD. Compared with participants with ApoE ε33, ε4 carriers (ε34/ε44) had significantly lower odds for having PD (OR, 0.75; 95% CI, 0.59-0.94; p = 0.01), whereas ε2 carriers (ε23/ε22) did not (OR, 0.95; 95% CI, 0.73-1.24; p = 0.71). Subgroup analyses showed similar results. In addition, we conducted a meta-analysis which confirmed our primary findings (ε34/ε44 vs ε33: OR, 0.90; 95% CI, 0.81-0.99; p = 0.024 and ε23/ε22 vs ε33: OR, 1.10; 95% CI, 0.97-1.23; p = 0.13). In PD patients, the prevalence of dementia appeared to be higher among ε4 carriers (compared with ε33: OR, 1.59; 95% CI, 0.98-2.58; p = 0.06), but lower among ε2 carriers (OR, 0.75; 95% CI, 0.40-1.42; p = 0.38), although neither test was statistically significant. Our study suggested that the ApoE ε4 allele may be associated with a lower PD risk among non-Hispanic Caucasians.
KW - Apolipoprotein E (ApoE)
KW - Association
KW - Dementia
KW - Parkinson disease (PD)
UR - http://www.scopus.com/inward/record.url?scp=80052627014&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2011.05.016
DO - 10.1016/j.neurobiolaging.2011.05.016
M3 - Article
C2 - 21741729
AN - SCOPUS:80052627014
SN - 0197-4580
VL - 32
SP - 2106.e1-2106.e6
JO - Neurobiology of Aging
JF - Neurobiology of Aging
IS - 11
ER -